Loading...
•
Sep 30, 2021
CRISPR Therapeutics Q3 2021 Earnings Report
CRISPR Therapeutics reported financial results for the third quarter ended September 30, 2021.
Key Takeaways
CRISPR Therapeutics reported a net loss of $127.2 million for the third quarter of 2021, compared to a net loss of $92.4 million for the third quarter of 2020. Total collaboration revenue was $0.3 million for the third quarter of 2021, compared to $0.1 million for the third quarter of 2020. Cash, cash equivalents and marketable securities were $2,477.4 million as of September 30, 2021, compared to $2,589.4 million as of June 30, 2021.
Target enrollment achieved in CTX001 clinical trials for beta thalassemia (TDT) and sickle cell disease (SCD); regulatory submissions planned for late 2022.
Positive results reported from the Phase 1 CARBON clinical trial evaluating CTX110™ for CD19+ B-cell malignancies; enrollment continues, with a potential registrational trial expected to start in Q1 2022.
Consolidation dosing protocols are being implemented for CTX120™ and CTX130™ clinical trials; enrollment continues, with top-line data expected in 1H 2022.
Regenerative medicine and in vivo programs continue to progress as planned.
Forward Guidance
CRISPR Therapeutics continues to advance its pipeline and expects to move multiple programs utilizing in vivo approaches into the clinic in the next 18 to 24 months.
Positive Outlook
- Planned regulatory submissions for CTX001 in late 2022.
- Potential registrational trial for CTX110 incorporating consolidation dosing expected to initiate in Q1 2022.
- Top-line data expected to report in 1H 2022 for CTX120™ and CTX130™ clinical trials.
- Phase 1/2 trial of allogeneic stem cell-derived therapy for Type 1 diabetes initiation remains on track for 2021.
- Multiple programs utilizing in vivo approaches expected to move into the clinic in the next 18 to 24 months.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...